Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member] Preferred Stock [Member]	Series A Preferred Stock [Member] Accumulated Deficit [Member]	Series C-1 Preferred Stock [Member]	Series C-1 Preferred Stock [Member] Accumulated Deficit [Member]	Series C-2 Preferred Stock [Member]	Series C-2 Preferred Stock [Member] Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2022	$ (37,790,539)	$ 897	$ 4,590,855	$ (42,382,291)
Beginning Balance (in Shares) at Dec. 31, 2022		896,580
Temporary equity accretion of dividends during the period					$ (164,510)		$ (164,510)	$ (40,551)	$ (40,551)	$ (470,962)	$ (470,962)
Exercise of common stock options	41,073	$ 21	41,052
Exercise of common stock options (in Shares)		21,158
Warrants issued in connection with notes	55,062		55,062
Change in par value of Common Stock		$ (827)	827
Business Combination with Alpha, net of transaction costs	55,382,354	$ 1,830	55,380,524
Business Combination with Alpha, net of transaction costs (in Shares)		18,302,510
Common stock issued to convertible noteholder at the Business Combination	250,000	$ 3	249,997
Common stock issued to convertible noteholder at the Business Combination (in Shares)		25,000
Common and Series A Preferred stock issued in conjuction with AxBio Acquisition	21,652,790	$ 385	21,652,404			$ 1
Common and Series A Preferred stock issued in conjuction with AxBio Acquisition (in Shares)		3,845,337				4,243
Stock-based compensation expense	605,299		605,299
Net loss	(18,602,436)			(18,602,436)
Ending Balance at Sep. 30, 2023	20,917,580	$ 2,309	82,576,020	(61,660,750)		$ 1
Ending Balance (in Shares) at Sep. 30, 2023		23,090,585				4,243
Beginning Balance at Jun. 30, 2023	(45,106,372)	$ 911	5,039,320	(50,146,603)
Beginning Balance (in Shares) at Jun. 30, 2023		911,058
Temporary equity accretion of dividends during the period					$ (12,655)		$ (12,655)	$ (2,912)	$ (2,912)	$ (33,811)	$ (33,811)
Exercise of common stock options	15,195	$ 7	15,188
Exercise of common stock options (in Shares)		6,680
Change in par value of Common Stock		$ (827)	827
Business Combination with Alpha, net of transaction costs	55,382,354	$ 1,830	55,380,524
Business Combination with Alpha, net of transaction costs (in Shares)		18,302,510
Common stock issued to convertible noteholder at the Merger	250,000	$ 3	249,997
Common stock issued to convertible noteholder at the Merger (in Shares)		25,000
Common and Series A Preferred stock issued in conjuction with AxBio Acquisition	21,652,790	$ 385	21,652,404			$ 1
Common and Series A Preferred stock issued in conjuction with AxBio Acquisition (in Shares)		3,845,337				4,243
Stock-based compensation expense	237,760		237,760
Net loss	(11,464,769)			(11,464,769)
Ending Balance at Sep. 30, 2023	20,917,580	$ 2,309	82,576,020	(61,660,750)		$ 1
Ending Balance (in Shares) at Sep. 30, 2023		23,090,585				4,243
Beginning Balance at Dec. 31, 2023	24,749,010	$ 2,309	83,250,101	(58,503,401)		$ 1
Beginning Balance (in Shares) at Dec. 31, 2023		23,090,585				4,243
Stock received from AxoBio Disposition	(23,456,179)	$ (385)	(23,455,793)			$ (1)
Stock received from AxoBio Disposition (in Shares)		(3,845,337)				(4,243)
Common Stock issued in connection with Promissory Notes	848,500	$ 33	848,467
Common Stock issued in connection with Promissory Notes (in Shares)		328,707
Common Stock issued	2,687,225	$ 134	2,687,091
Common Stock issued (in Shares)		1,331,452
Stock-based compensation expense	560,865		560,865
Net loss	(9,453,978)			(9,453,978)
Ending Balance at Sep. 30, 2024	(4,064,557)	$ 2,091	63,890,731	(67,957,379)
Ending Balance (in Shares) at Sep. 30, 2024		20,905,407
Beginning Balance at Jun. 30, 2024	(1,371,772)	$ 2,091	63,705,035	(65,078,898)
Beginning Balance (in Shares) at Jun. 30, 2024		20,905,407
Stock-based compensation expense	185,696		185,696
Net loss	(2,878,481)			(2,878,481)
Ending Balance at Sep. 30, 2024	$ (4,064,557)	$ 2,091	$ 63,890,731	$ (67,957,379)
Ending Balance (in Shares) at Sep. 30, 2024		20,905,407